Multiple classes of plant-derived compounds—including polyphenols like curcumin and resveratrol, flavonoids such as quercetin and genistein, and terpenoids like limonene—demonstrate anticancer activity against breast cancer through antioxidant, anti-inflammatory, and apoptosis-inducing mechanisms. These natural agents can inhibit tumor growth and modulate cellular signaling pathways while potentially enhancing conventional treatment effectiveness. This represents an encouraging convergence of traditional medicine wisdom with modern mechanistic understanding. Natural products offer a compelling adjunctive approach to breast cancer management, particularly given the severe side effects and high recurrence rates associated with current treatments. The ability of these compounds to work synergistically with conventional therapies could transform treatment protocols, potentially reducing chemotherapy doses while maintaining efficacy. However, significant hurdles remain before clinical implementation. Bioavailability issues plague many natural compounds, often requiring massive doses to achieve therapeutic tissue concentrations. Standardization challenges make dosing unpredictable, and regulatory pathways for natural products remain complex. While preclinical data appears promising, the transition to human trials has historically proven difficult for botanical medicines, making this an incremental rather than revolutionary development.